New drug combo aims to tame stubborn blood disorders
NCT ID NCT07574073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether combining two drugs (Zuberitamab and Orelabrutinib) can help people with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA) that hasn't responded to other treatments. The drugs work together to calm the immune system and stop it from attacking the body's own blood cells. The study will enroll 30 adults and focus on safety and how well the combination works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-CD20 MONOCLONAL ANTIBODY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an RNA 'Message' reprogram the immune system to stop autoimmune blood disorders?
- Can engineered immune cells tame autoimmune anemia?
- Can a bispecific antibody tame two autoimmune blood disorders?
- Can a gut bacteria transplant help when steroids fail for a bleeding disorder?
- Engineered immune cells take aim at stubborn blood disorder
- Will a new drug form work the same? study tests two versions of SKI-O-703